Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
32 hedge funds and large institutions have $9.48M invested in Acorda Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
0% more funds holding
Funds holding: 32 → 32 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
12% less call options, than puts
Call options by funds: $179K | Put options by funds: $203K
36% less capital invested
Capital invested by funds: $14.7M → $9.48M (-$5.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$972K |
| 2 |
CCA
Canyon Capital Advisors
Dallas,
Texas
|
+$882K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$357K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$294K |
| 5 |
Millennium Management
New York
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$186K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$124K |
| 3 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
-$69K |
| 4 |
Two Sigma Investments
New York
|
-$50K |
| 5 |
Renaissance Technologies
New York
|
-$36.4K |
ACOR Hedge Fund Activity: Q4 2021 in Review
32 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2021, worth a combined $9.48M — down 36% from $14.7M a quarter earlier.
Fund positioning in ACOR was balanced in Q4 2021: 5 funds opened new positions, 5 closed out, 12 added to existing stakes and 6 trimmed.
The largest buyer was Highbridge Capital Management, opening a new position worth an estimated $972K. The largest seller was AE Wealth Management, exiting entirely with an estimated $186K sold.
- 32 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $9.48M of Acorda Therapeutics stock for Q4 2021, down 36% quarter-over-quarter.
- 5 funds opened new Acorda Therapeutics positions in Q4 2021 and 5 closed out, a net change of 0 holders.
- The largest Acorda Therapeutics buyer in Q4 2021 was Highbridge Capital Management, an estimated $972K added.
- The largest Acorda Therapeutics seller in Q4 2021 was AE Wealth Management, an estimated $186K sold.
Based on aggregated 13F filings for Q4 2021.